Celldex Therapeutics’ (CLDX) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report report published on Thursday,Benzinga reports. Cantor Fitzgerald currently has a $67.00 price objective on the biopharmaceutical company’s stock.

CLDX has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Citigroup began coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Finally, The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Trading Up 4.0 %

NASDAQ CLDX opened at $26.81 on Thursday. The firm has a market capitalization of $1.78 billion, a P/E ratio of -10.43 and a beta of 1.57. The firm’s fifty day moving average price is $26.12 and its two-hundred day moving average price is $32.70. Celldex Therapeutics has a 1 year low of $22.93 and a 1 year high of $53.18.

Insider Activity

In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the stock in a transaction dated Monday, November 11th. The shares were bought at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 3.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its holdings in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics in the second quarter valued at about $76,000. Los Angeles Capital Management LLC lifted its position in Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares during the period. Quest Partners LLC grew its stake in Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 6,879 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 1,504 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.